BMS 981164

Drug Profile

BMS 981164

Alternative Names: BMS981164; IL-31 mAB - Bristol-Myers Squibb; IL-31 monoclonal antibody - Bristol-Myers Squibb

Latest Information Update: 21 Jun 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ZymoGenetics
  • Developer Bristol-Myers Squibb; ZymoGenetics
  • Class Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 31 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Atopic dermatitis; Inflammation

Most Recent Events

  • 01 Apr 2015 Bristol-Myers Squibb completes a phase I trial in Atopic dermatitis in United Kingdom (NCT01614756)
  • 16 Apr 2014 Bristol-Myers Squibb initiates enrolment in a phase I trial for Atopic dermatitis in United kingdom (UKCRN13421)
  • 01 Jul 2012 Phase-I clinical trials in Atopic dermatitis in United Kingdom (SC, IV) (NCT01614756)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top